There was an overall reduction of 34 percent in the rate of systemic recurrence (relative risk ,  0.66 ,  95 percent confidence interval ,  0.49 to 0.89 ,  P 0.006) in the group treated with combined therapy (75 of 164 patients vs. 94 of 154 patients in the group treated only with chemotherapy) ,  and a 17-percentage-point improvement in systemic disease-free survival (Fig. 2) .
